When a company develops, manufactures and delivers vaccines and therapeutics that take on the most serious global health threats, it’s not surprising to see their name in the headlines. And we are honored that for more than 20 years, Emergent has been one of those names. Included below are prominent news and feature stories that profile a range of our accomplishments through the years as well as advancements we’ve made in the technologies, processes and expertise needed to serve as a premier CDMO.
02.13.2021
Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing...
01.25.2021
GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. ...
12.01.2020
Excerpt taken from BioPharm International October 2020 Regulatory Sourcebook article titled: GMPs Guide COVID-19 Vaccine...
11.30.2020
Jee Look, senior director of drug product development for Emergent BioSolutions recently contributed to an article in ...
10.31.2020
With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past...
10.01.2020
Emergent BioSolutions, a Wells Fargo Corporate & Investment Banking customer since 2011, helps governments respond to health...